Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
M Gersel Stokholm, A Garrido, E Tolosa, M Serradell… - Journal of …, 2020 - Springer
M Gersel Stokholm, A Garrido, E Tolosa, M Serradell, A Iranzo, K Østergaard…
Journal of Neurology, 2020•SpringerNeuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have
been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of
LRRK2 G2019S mutation had 11 C-PK11195 and 18 F-DOPA PET to assess microglial
activation and striatal dopamine system integrity, respectively. Comparisons were made with
healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal 18 F-DOPA
uptake. Three of them had significantly raised nigral 11 C-PK11195 binding bilaterally …
been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of
LRRK2 G2019S mutation had 11 C-PK11195 and 18 F-DOPA PET to assess microglial
activation and striatal dopamine system integrity, respectively. Comparisons were made with
healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal 18 F-DOPA
uptake. Three of them had significantly raised nigral 11 C-PK11195 binding bilaterally …
Abstract
Neuroinflammation (microglial activation) and subclinical nigrostriatal dysfunction have been reported in subjects at risk of Parkinsonism. Eight non-manifesting carriers (NMCs) of LRRK2 G2019S mutation had 11C-PK11195 and 18F-DOPA PET to assess microglial activation and striatal dopamine system integrity, respectively. Comparisons were made with healthy controls. Five LRRK2-NMCs had subclinical reductions of putaminal 18F-DOPA uptake. Three of them had significantly raised nigral 11C-PK11195 binding bilaterally. These findings indicate that nigrostriatal dysfunction and neuroinflammation occur in LRRK2-NMCs. Studies in larger cohorts with appropriate follow-up are needed to elucidate the significance of neuroinflammation in the premotor phase of LRRK2-PD.
Springer
